Cargando…

Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial

BACKGROUND: This phase 2 trial aimed to compare adjuvant icotinib with observation in patients with epidermal growth factor receptor (EGFR) mutation-positive resected stage IB non-small cell lung cancer (NSCLC). METHODS: We performed a randomised, open-label, phase 2 trial from May 1, 2015 to Decemb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou, Wei, Li, Ning, Wang, Bao-Xiao, Zhu, Teng-Fei, Shen, Zhi-Lin, Wang, Tao, Chang, Wu-Guang, Chang, Zeng-Hao, Hu, Xin-Xin, Pu, Yue, Ding, Lie-Ming, Wang, Si-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932314/ https://www.ncbi.nlm.nih.gov/pubmed/36816343 http://dx.doi.org/10.1016/j.eclinm.2023.101839

Ejemplares similares

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
por: Xia, Pinghui, et al.
Publicado: (2018)

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
por: Feng, Siyang, et al.
Publicado: (2015)

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
por: Wilgucki, Molly, et al.
Publicado: (2022)

Associations between potentially functional CORIN SNPs and serum corin levels in the Chinese Han population
por: Zhang, Huan, et al.
Publicado: (2019)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
por: Ye, Chenyang, et al.
Publicado: (2016)

Discussion Session, 8 Jul 1003
por: Joram, C, et al.
Publicado: (2003)

Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR
por: Chen, Hua-Fei, et al.
Publicado: (2019)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
por: Zhang, Yun, et al.
Publicado: (2021)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
por: Liu, Yu-Tao, et al.
Publicado: (2020)

Corin Deficiency Diminishes Intestinal Sodium Excretion in Mice
por: Gu, Xiabing, et al.
Publicado: (2023)

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials
por: Zhang, Shu-Ling, et al.
Publicado: (2023)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Standardisation of realtime software POSIX 1003.4
por: Eck, C
Publicado: (1991)

Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study
por: Zeng, Ziqing, et al.
Publicado: (2020)

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
por: Cui, Jiadong, et al.
Publicado: (2018)

Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis
por: Qu, Jian, et al.
Publicado: (2017)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion
por: Zu, Yunfen, et al.
Publicado: (2021)

Renal Corin Is Essential for Normal Blood Pressure and Sodium Homeostasis
por: Zhou, Tiantian, et al.
Publicado: (2022)

The protease corin regulates electrolyte homeostasis in eccrine sweat glands
por: He, Meiling, et al.
Publicado: (2021)

The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
por: Lin, Chutong, et al.
Publicado: (2021)

Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients
por: Tan, Xueyun, et al.
Publicado: (2023)

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases
por: Xu, Jian‐ping, et al.
Publicado: (2016)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations
por: Yao, Shuyang, et al.
Publicado: (2016)

Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma
por: Wang, Xi, et al.
Publicado: (2016)

Serum corin is associated with the risk of chronic heart failure
por: Yu, Zongliang, et al.
Publicado: (2017)

Corin—The Early Marker of Preeclampsia in Pregestational Diabetes Mellitus
por: Boroń, Daniel, et al.
Publicado: (2022)

Impuesto al gasto /
por: Kaldor, Nicholas, 1908-1986
Publicado: (1963)

Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice
por: Wang, Wei, et al.
Publicado: (2012)

Corin deficiency impairs cardiac function in mouse models of heart failure
por: Niu, Yayan, et al.
Publicado: (2023)

Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report
por: Zhang, Ping, et al.
Publicado: (2018)

Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)
por: Lv, C., et al.
Publicado: (2023)

Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
por: Zhang, Ningning, et al.
Publicado: (2019)

Icotinib-resistant HCC827 cells produce exosomes with mRNA MET oncogenes and mediate the migration and invasion of NSCLC
por: Yu, Yiming, et al.
Publicado: (2019)

Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells
por: Wang, Xuanxuan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_npj2aiaoa7mklfbkin6nicaa31